AstraZeneca mulls delisting its Indian arm
This article was originally published in Scrip
Executive Summary
AstraZeneca may take another shot at delisting its Indian arm by buying the residual 10% in its Indian arm, AstraZeneca Pharma India, against a backdrop of amendments to listing rules in India that mandate a minimum threshold level of public holding of 25% for all listed companies by 2013, as against 10% earlier.